Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288293 | 0.78 | USP30 (0.44) | USP30IRAK4BRD4 | |
| SCHEMBL22133036 | 0.73 | IRAK4 (0.34) | IRAK4ALOX5APFEN1ALOX5CYP2C9 | |
| SCHEMBL30288294 | 0.73 | IRAK4 (0.41) | IRAK4ALOX5AP | |
| SCHEMBL20662094 | 0.69 | IRAK4 (0.35) | IRAK4ALOX5APFEN1ALOX5CYP2C9 | |
| SCHEMBL23519500 | 0.68 | CHRM4 (0.39) | USP30IRAK4CYP2C9BRD4 | |
| SCHEMBL15730719 | 0.67 | ALK (0.33) | IRAK4ALOX5APFEN1ALOX5CYP2C9 | |
| SCHEMBL28866429 | 0.66 | CHUK (0.46) | USP30 | |
| SCHEMBL18418875 | 0.66 | ALK (0.39) | IRAK4 | |
| SCHEMBL23388963 | 0.66 | UTS2R (0.43) | BCL6 | |
| SCHEMBL23863553 | 0.65 | ALOX5AP (0.58) | IRAK4ALOX5APFEN1ALOX5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | USP30 3326/4885IRAK4 1706/4885ALOX5AP 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.